יחס מהיר intracellulartherapies.com (ITCI)

Intra-Cellular Therapies (ITCI) leads the development of psychoneurological treatments, building on the success of Caplyta and expanding its reach to patients with depression. Driven by operating profit growth and free cash flow inflows, the company has minimized its debt load, which currently stands at 6.17. The price trend illustrated in this chart complements the picture of financial stability. The business relies on the diversification of therapies for bipolar disorders and schizophrenia, funding new research through current sales.

For the long-term investor, the stability of Intra-Cellular Therapies (ITCI) is determined by its ability to meet obligations without liquidating inventory. The quick ratio assesses the relationship between cash and accounts receivable relative to short-term debt, excluding illiquid goods. By analyzing the current quick ratio, one can evaluate the company's financial reserve in the event of regulatory pressure or patent disputes. A high ratio confirms business autonomy despite the dependence on the commercial success of Caplyta.